Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 3 9Phase EARLY_PHASE1 6Phase 1 5Phase NA 4Phase 2/3 4Phase 1/2 3Phase 4 2

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Breast 1

Conditions

Multiple Myeloma 2Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Aspirin × Clear all
NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

The Methodist Hospital Research Institute

Phase 1/2 Completed
37 enrolled 20 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01355705 2018-09-18

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Stanford University

Phase 1/2 Completed
14 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT00833833 2016-04-27

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Celgene Corporation

Phase 1/2 Completed
259 enrolled 31 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡